Faron Pharmaceuticals Oy (FRA:4FR) Tariff Resilience Score: 0/10 (As of Jul. 09, 2026)


FRA:4FR Faron Pharmaceuticals Oy FRA:4FR
21 GF Score
Price €0.48
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy Tariff Resilience Score?

Faron Pharmaceuticals Oy has the Tariff Resilience Score of 0, which implies that the company might have .

Faron Pharmaceuticals Oy has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Faron Pharmaceuticals Oy might have .

Faron Pharmaceuticals Oy  (FRA:4FR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Faron Pharmaceuticals Oy Tariff Resilience Score Related Terms

FRA:4FR
21GF Score
Faron Pharmaceuticals Oy FRA:4FR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARN:UKFARON:Finland
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
21GF Score

Get the complete analysis for FRA:4FR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.48
Price